Bioventus (BVS) vs CeriBell (CBLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CeriBell (CBLL) has outperformed Bioventus (BVS) over the past year, gaining 99.0% versus a gain of 92.0%. CeriBell is the larger company by market cap ($889.0 million vs $866.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | CBLL |
|---|---|---|
| Share price | $12.68 | $23.17 |
| Market cap | $866.11M | $889.03M |
| 1-day change | -0.70% | -1.34% |
| YTD return | +71.64% | +7.07% |
| 1-year return | +92.03% | +98.98% |
| 5-year return | -6.38% | — |
| P/E ratio (TTM) | 16.26 | — |
| Forward P/E | 13.78 | — |
| EPS (TTM) | $0.78 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $25.63 |
| 52-week low | $6.37 | $10.85 |
| Distance from 52-week high | -20.22% | -9.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +38.80% | +23.33% |
| Average volume | 619.63K | 368.86K |
| Shares outstanding | 68.31M | 38.38M |
| Employees | 950 | 327 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 950 employees
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
BVS vs CBLL FAQ
Which is bigger, Bioventus or CeriBell?
CeriBell (CBLL) is larger, with a market capitalization of $889.03M compared with $866.11M for Bioventus (BVS).
Which stock has performed better over the past year, BVS or CBLL?
CBLL returned +98.98% over the past 12 months, compared with +92.03% for BVS (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and CeriBell in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Bioventus and Biotechnology: Electromedical & Electrotherapeutic Apparatus for CeriBell.